GLP1减重宝典·2025-09-02 12:49Core Viewpoint - The article discusses the competitive landscape of GLP-1 medications, particularly focusing on the recent STEER real-world study results that highlight the cardiovascular benefits of semaglutide (Wegovy) compared to tirzepatide, emphasizing its unique position in the market for patients with obesity and cardiovascular disease without diabetes [3][5][8]. Group 1: Study Results - The STEER study showed that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by up to 57% in patients with cardiovascular disease and obesity, with only 0.1% of events occurring in the semaglutide group compared to 0.4% in the tirzepatide group [5][7]. - Even when including patients with treatment interruptions, semaglutide still demonstrated a 29% risk reduction in cardiovascular events over an average follow-up of 8.3 months [5][7]. Group 2: Market Performance - In the first half of 2025, semaglutide generated sales of $16.632 billion, leading the global pharmaceutical sales, while tirzepatide followed closely with $14.734 billion, surpassing semaglutide in quarterly sales for the first time in Q2 2025 [11]. - Tirzepatide's dual mechanism (GLP-1/GIP) has shown superior weight loss results, averaging an additional weight loss of approximately 8 kg compared to semaglutide over 72 weeks [11]. Group 3: Competitive Dynamics - The results from the STEER study provide semaglutide with a differentiated advantage, particularly for older patients or those at high cardiovascular risk, potentially influencing physician prescribing habits and insurance reimbursement acceptance [13]. - The competition among GLP-1 drugs is evolving beyond just weight loss to a more tailored approach, matching the right drug to the appropriate patient population [13].